IGF-1 and Growth Response to Adult Height in a Randomized GH Treatment Trial in Short Non-GH-Deficient Children

被引:31
|
作者
Kristrom, Berit [1 ,3 ]
Lundberg, Elena [1 ]
Jonsson, Bjorn [2 ]
Albertsson-Wikland, Kerstin [3 ]
机构
[1] Umea Univ, Dept Clin Sci, SE-90185 Umea, Sweden
[2] Uppsala Univ, Dept Womens & Childrens Hlth, SE-75185 Uppsala, Sweden
[3] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Goteborg Pediat Growth Res Ctr,Dept Pediat, SE-41685 Gothenburg, Sweden
来源
基金
瑞典研究理事会;
关键词
IDIOPATHIC SHORT STATURE; FOR-GESTATIONAL-AGE; LONG-TERM MORTALITY; HORMONE TREATMENT; BINDING PROTEIN-3; FACTOR-I; PREPUBERTAL CHILDREN; FINAL HEIGHT; SECRETION CAPACITIES; PREDICTION MODELS;
D O I
10.1210/jc.2014-1101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: GH treatment significantly increased adult height (AH) in a dose-dependent manner in short non-GH-deficient children in a randomized, controlled, clinical trial; the mean gain in height SD score (height(SDS)) was 1.3 (range 0-3), compared with 0.2 in the untreated group. Objective: The objective of the study was to analyze the relationship between IGF-1(SDS), IGF binding protein-3 SDS (IGFBP3(SDS)), and their ratio(SDS) with a gain in the height(SDS) until AH in non-GH-deficient short children. Design and Setting: This was a randomized, controlled, multicenter clinical trial. Intervention: The intervention included GH treatment: 33 or 67 mu g/kg.d plus untreated controls. Subjects: One hundred fifty-one non-GH-deficient short children were included in the intent-to-treat (ITT) population and 108 in the per-protocol (PP) population; 112 children in the ITT and 68 children in the PP populations had idiopathic short stature (ISS). Main Outcome Measures: Increments from baseline to on-treatment study mean IGF-1(SDS) (Delta IGF-1(SDS)), IGFBP3(SDS), and IGF-1 to IGFBP3 ratio(SDS) were assessed in relationship to the gain in height(SDS). Results: Sixty-two percent of the variance in the gain in height(SDS) in children on GH treatment could be explained by four variables: Delta IGF-1(SDS) (explaining 28%), bone age delay, birth length (the taller the better), and GH dose (the higher the better). The lower IGF-1(SDS) was at baseline, the higher was its increment during treatment. For both the All(PP)- and the ISSPP-treated groups, the attained IGF-1(SDS) study level did not correlate with height gain. Conclusion: In short non-GH-deficient children, the GH dose-related increment in IGF-1(SDS) from baseline to mean study level was the most important explanatory variable for long-term growth response from the peripubertal period until AH, when IGF-1(SDS), IGFBP3(SDS), and their ratio(SDS) were compared concurrently.
引用
收藏
页码:2917 / 2924
页数:8
相关论文
共 50 条
  • [1] EFFECT OF HGH TREATMENT ON GROWTH OF NON-GH-DEFICIENT SHORT CHILDREN
    LENKO, HL
    PERHEENTUPA, J
    PEDIATRIC RESEARCH, 1975, 9 (08) : 671 - 671
  • [2] EFFECTIVENESS OF GROWTH-HORMONE (GH) THERAPY IN GH-DEFICIENT CHILDREN AND NON-GH-DEFICIENT SHORT CHILDREN
    BOZZOLA, M
    CISTERNINO, M
    BISCALDI, I
    MAGHNIE, M
    VALTORTA, A
    MORETTA, A
    SEVERI, F
    EUROPEAN JOURNAL OF PEDIATRICS, 1988, 147 (03) : 248 - 251
  • [3] GROWTH-HORMONE THERAPY IN NON-GH-DEFICIENT SHORT CHILDREN
    VACCARO, F
    CIANFARANI, S
    SPADONI, GL
    SPAGNOLI, A
    BERNARDINI, S
    GALASSO, C
    BOSCHERINI, B
    RIVISTA ITALIANA DI PEDIATRIA-ITALIAN JOURNAL OF PEDIATRICS, 1990, 16 (05): : 528 - 534
  • [5] Management of Short Stature: Use of Growth Hormone in GH-Deficient and non-GH-Deficient Conditions
    Vyas, Varuna
    Menon, Ram K.
    INDIAN JOURNAL OF PEDIATRICS, 2021, 88 (12): : 1203 - 1208
  • [6] Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH
    Blethen, SL
    Baptista, J
    Kuntze, J
    Foley, T
    LaFranchi, S
    Johanson, A
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02): : 418 - 420
  • [8] Combination therapy with GH and cyproterone acetate does not improve final height in boys with non-GH-deficient short stature
    Kawai, M
    Momoi, T
    Yorifuji, T
    Muroi, J
    Yamanaka, C
    Sasaki, H
    Furusho, K
    CLINICAL ENDOCRINOLOGY, 1998, 48 (01) : 53 - 57
  • [9] Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents
    Ranke, MB
    Schweizer, R
    Elmlinger, MW
    Weber, K
    Binder, G
    Schwarze, CP
    Wollmann, HA
    HORMONE RESEARCH, 2001, 55 (03) : 115 - 124
  • [10] EFFECTS OF SYSTEMIC GROWTH-HORMONE (GH) ADMINISTRATION ON REGIONAL ADIPOSE-TISSUE IN CHILDREN WITH NON-GH-DEFICIENT SHORT STATURE
    ROSENBAUM, M
    GERTNER, JM
    GIDFAR, N
    HIRSCH, J
    LEIBEL, RL
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (01): : 151 - 156